Status:

WITHDRAWN

Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy

Lead Sponsor:

Montefiore Medical Center

Conditions:

Ventricular Tachycardia

Eligibility:

All Genders

18-99 years

Phase:

EARLY_PHASE1

Brief Summary

This is a prospective multicenter randomized open-label study aiming to assess whether endocardial or endocardial-epicardial ablation is superior to the standard approach (i.e., Antiarrhythmic drugs) ...

Detailed Description

Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy (EPI VT) is a prospective multicenter randomized controlled study that is planned as a pilot study to...

Eligibility Criteria

Inclusion

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 or greater
  • Patient with ≥ 1 episode of VT (i.e., Sustained VT more than 30 seconds or VT with any ICD therapy)
  • Patients with ischemic cardiomyopathy, EF less than 50%, documented history of CAD

Exclusion

  • Patients with ventricular fibrillation.
  • Reversible causes of VT.
  • Patients with contraindications to systemic anticoagulation with heparin or coumadin, direct thrombin inhibitor or factor Xa inhibitors.
  • Patients with prior procedure involving opening the pericardium or entering the pericardial space (e.g., CABG, heart transplantation, valve surgery) were adhesions are suspected
  • Any prior ablation for the ventricles or any prior epicardial ablation
  • Documented history of myocardial infarction within 1 month prior to the planned study intervention
  • Documented symptomatic carotid disease defined as \> 70% stenosis or \> 50% stenosis with symptoms
  • Any history of thoracic radiation with the exception of localized radiation treatment for breast cancer
  • Active pericarditis
  • Active endocarditis\\Any documented history or autoimmune disease associated with pericarditis
  • Thrombocytopenia (platelet count \< 100 x 109/L)
  • Body Mass Index (BMI \> 45)
  • Patients who are pregnant.
  • Pregnancy will be assessed by urine pregnancy testing prior to the ablation procedure

Key Trial Info

Start Date :

January 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 23 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04512911

Start Date

January 1 2023

End Date

January 23 2023

Last Update

October 6 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Montefiore Medical Center, Cardiology

The Bronx, New York, United States, 10467